Spots Global Cancer Trial Database for lgx818
Every month we try and update this database with for lgx818 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | NCT02631447 | Metastatic Mela... | LGX818 MEK162 Nivolumab Ipilimumab | 18 Years - | Fondazione Melanoma Onlus | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | NCT02159066 | Melanoma | LGX818 MEK162 LEE011 BGJ398 BKM120 INC280 | 18 Years - | Pfizer | |
| A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | NCT01543698 | Solid Tumors Ha... | LGX818 MEK162 LEE011 | 18 Years - | Pfizer | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | NCT02109653 | Non-Small Cell ... | LGX818 | 18 Years - | Array BioPharma | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| LGX818 for Patients With BRAFV600 Mutated Tumors | NCT01981187 | Solid Tumor Hematologic Mal... | LGX818 | 18 Years - | Pfizer | |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | NCT02278133 | Metastatic Colo... | WNT974 LGX818 Cetuximab | 18 Years - | Array BioPharma | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | NCT02278133 | Metastatic Colo... | WNT974 LGX818 Cetuximab | 18 Years - | Array BioPharma | |
| LGX818 for Patients With BRAFV600 Mutated Tumors | NCT01981187 | Solid Tumor Hematologic Mal... | LGX818 | 18 Years - | Pfizer | |
| BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | NCT01894672 | Melanoma | LGX818 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | NCT01436656 | Melanoma and Me... | LGX818 | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
